Study of Bavarian Nordic's monkeypox vaccine raises questions about protection

New research suggest that Jynneos, the world’s only vaccine against the monkeypox infection that is made by the Danish drugmaker, provides less protection than hoped.

Photo: Sven Hoppe/AP/Ritzau Scanpix

The monkeypox vaccine that’s become the main method doctors are using to try to stop the global scourge may be less potent than hoped, new research shows.

The recommended series of shots with Bavarian Nordic A/S’s Jynneos vaccine yielded relatively low levels of monkeypox antibodies with poor neutralizing capacity, researchers at the Erasmus University Medical Center in Rotterdam, Netherlands, said. Those immunized hadn’t been previously infected or vaccinated against smallpox, which is believed to provide some protection against monkeypox.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Further reading

Related articles

Latest news

See all jobs